Roxithromycin 300MG TABLET indications
Roxithromycin 300MG TABLET is indicated for the treatment of the following types of mild to
moderately severe infections caused by or likely to be caused by susceptible
micro-organisms: • upper respiratory tract infection - acute pharyngitis, tonsillitis and
• dental infections
• lower respiratory tract infection - acute bronchitis; acute exacerbations
of chronic bronchitis and community acquired pneumonia
• skin and skin structure infections
• non-gonococcal urethritis.
Uses of Roxithromycin 300MG TABLET in details
Roxithromycin 300MG TABLET is used to treat ear, nose and throat infections, pneumonia (lung infection), skin infections and infections of the genitalia.
Roxithromycin 300MG TABLET description
Roxithromycin 300MG TABLET is a semi-synthetic macrolide antibiotic. It is very similar in composition, chemical structure and mechanism of action to erythromycin, azithromycin, or clarithromycin. Roxithromycin 300MG TABLET prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin 300MG TABLET binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin 300MG TABLET has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila. It can treat respiratory tract, urinary and soft tissue infections. It is in the United States, but is available in Australia.
Roxithromycin 300MG TABLET dosage
Adult: 150 mg bid or 300 mg once daily for 5-10 days in susceptible infections.
Child: 6-40 kg: 5-8 mg/kg daily.
Renal impairment: Dosage adjustment may be required.
Hepatic impairment: Usual daily doses should be halved in hepatic impairment.
Roxithromycin 300MG TABLET interactions
Roxithromycin 300MG TABLET has a much lower affinity for cytochrome P450 than
erythromycin, and consequently has fewer interactions. Interactions may be
observed, however, with drugs that bind to alpha-1-acid glycoprotein, e.g.
Roxithromycin 300MG TABLET does not appear to interact with oral contraceptives,
prednisolone, carbamazepine, ranitidine or antacids.
Theophylline. A study in normal subjects concurrently administered
Roxithromycin 300MG TABLET and theophylline has shown some increase in the plasma
concentration of the latter. While a change in dosage is usually not required,
patients with high levels of theophylline at commencement of treatment
should have levels monitored.
Ergot alkaloids. Reactions of ergotism with possible peripheral necrosis have
been reported after concomitant therapy of macrolides with vasoconstrictive ergot alkaloids, particularly ergotamine and dihydroergotamine. Because a
clinical interaction with Roxithromycin 300MG TABLET cannot be excluded, administration of
Roxithromycin 300MG TABLET to patients taking ergot alkaloids is contraindicated.
Disopyramide. An in vitro study has shown that Roxithromycin 300MG TABLET can displace
protein bound disopyramide; such an effect in vivo could result in increased
serum levels of disopyramide. Consequently, ECG and, if possible,
disopyramide serum levels should be monitored.
Terfenadine. Some macrolide antibiotics (e.g. erythromycin) may increase
serum levels of terfenadine. This can result in severe cardiovascular adverse
events, including QT prolongation, torsades de pointes and other ventricular
arrhythmias. Such a reaction has not been documented with Roxithromycin 300MG TABLET,
which has a much lower affinity for cytochrome P450 than erythromycin.
However, in the absence of a systematic interaction study, concomitant
administration of Roxithromycin 300MG TABLET and terfenadine is not recommended.
Astemizole, cisapride, pimozide. Other drugs, such as astemizole, cisapride
or pimozide, which are metabolised by the hepatic isozyme CYP3A4, have
been associated with QT interval prolongation and/or cardiac arrhythmias
(typically torsades de pointes) as a result of an increase in their serum level
subsequent to interaction with significant inhibitors of this isozyme, including
some macrolide antibacterials. Although Roxithromycin 300MG TABLET has no or limited ability
to complex CYP3A4 and hence to inhibit the metabolism of other drugs
processed by this isozyme, a potential for clinical interaction of Roxithromycin 300MG TABLET
with the above mentioned drugs cannot be either ascertained or ruled out in
confidence. Thus, concomitant administration of Roxithromycin 300MG TABLET and such drugs
is not recommended.
Warfarin. While no interaction was observed in volunteer studies,
Roxithromycin 300MG TABLET appears to interact with warfarin. Increases in prothrombin time
(international normalised ratio (INR)) have been reported in patients treated
concomitantly with Roxithromycin 300MG TABLET and warfarin or the related vitamin K
antagonist phenprocoumon, and severe bleeding episodes have occurred as
Digoxin and other cardiac glycosides. A study in healthy volunteers has
shown that Roxithromycin 300MG TABLET may increase the absorption of digoxin. This effect,
common to other macrolides, may very rarely result in cardiac glycoside
toxicity. This may be manifested by symptoms such as nausea, vomiting,
diarrhoea, headache or dizziness. Cardiac glycoside toxicity may also elicit
heart conduction and/or rhythm disorders. Consequently, in patients treated
with Roxithromycin 300MG TABLET and digoxin or another cardiac glycoside, ECG and, if
possible, the serum level of the cardiac glycoside should be monitored. This is
mandatory if symptoms suggesting cardiac glycoside overdosage have
Midazolam. Roxithromycin 300MG TABLET, like other macrolides, may increase the area
under the midazolam concentration-time curve and the midazolam half-life.
Thus, the effects of midazolam may be enhanced and prolonged in patients treated with Roxithromycin 300MG TABLET. There is no conclusive evidence for an interaction
between Roxithromycin 300MG TABLET and triazolam.
Cyclosporin. A slight increase in plasma concentrations of cyclosporin A has
been observed. This does not generally necessitate altering the usual dosage.
Roxithromycin 300MG TABLET side effects
Applies to benzoyl peroxide topical: topical bar, topical cream, topical foam, topical gel/jelly, topical liquid, topical lotion, topical pad, topical soap, topical solution
In addition to its needed effects, some unwanted effects may be caused by benzoyl peroxide topical (the active ingredient contained in Roxithromycin 300MG TABLET). In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking benzoyl peroxide topical:
Less common or rare:
- Painful irritation of skin, including burning, blistering, crusting, itching, severe redness, or swelling
- skin rash
- Difficult breathing
- swelling of the eyes, face, lips, or tongue
- tightness in the throat
If any of the following symptoms of overdose occur while taking benzoyl peroxide topical, get emergency help immediately:
Symptoms of overdose:
- Burning, itching, scaling, redness, or swelling of skin (severe)
Minor Side Effects
Some of the side effects that can occur with benzoyl peroxide topical may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
- Dryness or peeling of the skin (may occur after a few days)
- feeling of warmth, mild stinging, and redness of the skin
Roxithromycin 300MG TABLET contraindications
Hypersensitivity to Roxithromycin 300MG TABLET or macrolides including erythromycin. Severely impaired hepatic function. Vasoconstrictive ergot alkaloids.
Active ingredient matches for Roxithromycin 300MG TABLET:
- PubChem. "roxithromycin". https://pubchem.ncbi.nlm.nih.gov/compoun... (accessed September 18, 2017).
ReviewsThe results of a survey conducted on ndrugs.com for Roxithromycin 300MG TABLET are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Roxithromycin 300MG TABLET. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Information checked by Dr. Sachin Kumar, MD Pharmacology